Related Experiment Video
Updated: May 25, 2026
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
[Cardiotoxicity of anthracyclines].
Irina-Iuliana Costache1, A Petriş
1Disciplina de Medicină internă, Facultatea de Medicină, Universitatea de Medicină şi Farmacie "Gr. T. Popa" Iaşi.
Summary
Anthracycline chemotherapy can cause dose-related heart damage, increasing cardiovascular risks, especially in breast cancer patients. Understanding cardiotoxicity mechanisms and risk factors is crucial for developing preventative strategies.
Area of Science:
- Oncology
- Cardiology
- Toxicology
Context:
- Anthracyclines are vital antitumor agents.
- Breast cancer treatments may exacerbate anthracycline-induced cardiotoxicity.
- Cardiotoxicity significantly increases cardiovascular morbidity and mortality.
Purpose:
- To review the mechanisms, clinical manifestations, and risk factors of anthracycline cardiotoxicity.
- To discuss current and emerging strategies for mitigating anthracycline-induced cardiac damage.
Summary:
- Anthracycline cardiotoxicity presents acutely, early, or late, involving complex mechanisms like free radical production and myocyte damage.
- Key risk factors include cumulative dose, age, concurrent chemotherapy, and pre-existing heart conditions.
- Management strategies involve novel infusion protocols, new drug development, adjunctive agents, and cardiac function monitoring.
Impact:
- Highlights the significant cardiovascular risks associated with anthracycline chemotherapy.
- Emphasizes the need for proactive monitoring and risk reduction strategies in cancer patients.
- Informs clinical practice and future research for safer cancer treatment protocols.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...